In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Trends: Nowhere To Go But Up

Executive Summary

Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty
Advertisement

Related Content

A Look Back At 2010: In Search Of New Biopharma Models
Best of The IN VIVO Blog (02/2010)
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2009
2009's Top Biopharma Dealmakers
Lilly Tries to Buy Time
Health Care Reform and Business Development: 10 Reasons It Matters
Can BMS Deliver on Innovation?
Dealmaking When Pharma's the Only Game in Town
Merck Buys Schering-Plough -- and Time
Pfizer/Wyeth: Industrializing Pharma?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel